# Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

> **NCT00673231** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1240 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin
- **DRUG:** Placebo
- **DRUG:** Dapagliflozin
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT00673231
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-05
- **Final completion:** 2011-01
- **Target enrollment:** 1240 (ACTUAL)
- **Last updated:** 2013-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673231, "Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00673231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*